Home › Therapeutic areas › Neurology › Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (16 companies)
Companies with an active program in Amyotrophic Lateral Sclerosis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 1 | Phase 3 | $3.79B | 5 |
| ANNX | Annexon | HematologyNeurology+2 Rare | 1 | Phase 3 | $796M | 6 |
| CRVO | CervoMed | Neurology Rare | 1 | Phase 2 | $21.5M | 4 |
| CLNN | Clene | Neurology Rare | 1 | NDA Submitted | $56.9M | 5 |
| COYA | Coya Therapeutics | Neurology Rare | 1 | Phase 2 | $70.1M | 6 |
| ELDN | Eledon Pharmaceuticals | ImmunologyMetabolic+1 Rare | 1 | Phase 2 | $212M | 3 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 1 | Approved | $25.1B | 15 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 3 | Approved | $6.55B | 29 |
| KROS | Keros Therapeutics | NeurologyOncology Rare | 1 | Phase 3 | $184M | 5 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 1 | Phase 3 | $864M | 16 |
| NRSN | NeuroSense Therapeutics | Neurology Rare | 1 | Phase 2 | $3.2M | 3 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 1 | Approved | $103M | 7 |
| KTTA | Pasithea Therapeutics | NeurologyOncology Rare | 1 | Phase 1 | $19.3M | 4 |
| PMN | ProMIS Neurosciences | Neurology Rare | 1 | Phase 1 | $37.3M | 6 |
| TLSA | Tiziana Life Sciences | ImmunologyNeurology Rare | 1 | Phase 2 | $87.8M | 5 |
| VYGR | Voyager Therapeutics | MetabolicNeurology Rare | 2 | Phase 1 | $116M | 9 |
No companies match.